We are a clinical-stage pharmaceutical company developing new therapeutics for serious and debilitating diseases involving chronic inflammation.
Our pipeline focuses on patient populations at high risk for cardiovascular disease comorbidities because of an underlying chronic inflammatory disorder.
Target Oxidized Lipoproteins
Our products target oxidized lipoproteins, such as low-density lipoprotein (oxLDL) and lipoprotein(a). Oxidized lipoproteins are potent inflammatory mediators that are implicated in several inflammatory diseases.
How It Works
Treat Inflammatory Disease
Our clinical and preclinical programs are focused on addressing unmet needs in inflammatory diseases including plaque psoriasis, accelerated atherosclerosis and aortic valve stenosis.